Trials / Completed
CompletedNCT01781455
A Study of BBI503 in Adult Patients With Advanced Solid Tumors
A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 311 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single arm dose escalation study of BBI503 in adult patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BBI503 |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2020-06-01
- Completion
- 2020-06-01
- First posted
- 2013-02-01
- Last updated
- 2023-11-14
Locations
19 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01781455. Inclusion in this directory is not an endorsement.